GlassScriptPhysician profile
Lauren Strazzulla
NPI 1861989238
$5,717.89
in general payments reported to CMS, 2019-2025
22 companies · $1,271 in 2025
The $1,271 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $171 · 2021: $592 · 2022: $1,989 · 2023: $480 · 2024: $720 · 2025: $1,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,465 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,465.49 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,390.63 | 2019-2022 | |
| Abbvie INC. | $769.27 | 2020-2024 | |
| Regeneron Healthcare Solutions, INC. | $755.39 | 2019-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $710.66 | 2022-2025 | Winlevi, Ilumya |
| Galderma Laboratories, L.P. | $333.26 | 2021-2022 | |
| Pfizer INC. | $270.05 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $199.42 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $186.02 | 2021-2025 | Jublia, Arazlo, Cabtreo |
| Genzyme Corporation | $152.44 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $138.68 | 2025 | |
| Celgene Corporation | $137.34 | 2019 | |
| Incyte Corporation | $124.75 | 2023-2025 | Opzelura |
| Organon LLC | $88.71 | 2025 | Vtama |
| Janssen Biotech, INC. | $88.31 | 2025 | Tremfya |
| Dermavant Sciences, INC. | $81.42 | 2024 | Vtama |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $76.50 | 2025 | Bimzelx |
| Leo Pharma INC. | $71.18 | 2025 | Adbry |
| Amgen INC. | $56.04 | 2025 | Otezla |
| Lilly USA, LLC | $26.83 | 2025 | Ebglyss |
| Botanix Sb INC | $23.75 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $20.07 | 2024 | Zoryve |
| Helsinn Therapeutics (U.S.), INC. | $17.17 | 2025 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Strazzulla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.